Director Paul Stuka filed a Form 4 with the SEC on November 19, 2026, disclosing an open-market purchase of 30,000 shares of InspireMD, Inc. common stock on November 17, 2026.

Key Highlights

  • Transaction: Paul Stuka acquired 30,000 shares of InspireMD common stock via open-market purchase (transaction code P) on November 17, 2026.
  • Price: Shares were purchased at $0.58 each, in multiple transactions all at the reported price, according to the filing.
  • Direct ownership after transaction: Stuka directly holds 697,871 shares of common stock following the reported purchase.
  • Indirect holdings: An additional 731,397 shares are held indirectly through Osiris Investment Partners, L.P., of which Stuka is the managing member of the general partner.
  • Disclaimer: Stuka disclaims beneficial ownership of the Osiris-held shares except to the extent of his pecuniary interest, per the filing.
  • Issuer: InspireMD, Inc. trades on NASDAQ:NSPR.

Stuka's Open-Market Purchase of InspireMD Common Stock

According to the Form 4 filed November 19, 2026, Paul Stuka, a director of InspireMD, Inc. (NASDAQ:NSPR), purchased 30,000 shares of the company's common stock on November 17, 2026. The filing states the shares were acquired in multiple open-market transactions, all at a price of $0.58 per share. Following this acquisition, Stuka directly beneficially owns 697,871 shares of common stock.

The filing also reports 731,397 shares held indirectly through Osiris Investment Partners, L.P. ("Osiris"). The reporting person serves as the managing member of Osiris Partners, LLC, the general partner of Osiris, through which he "may be deemed to beneficially own" those shares. However, the filing notes that Stuka "disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein," and specifies that "the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purposes." No transaction was effected with respect to the Osiris-held shares; they are reported for informational purposes only.

The Form 4 was signed by Michael Lawless as Attorney-in-Fact for Paul Stuka and filed on November 19, 2026, the date of earliest transaction being November 17, 2026. No derivative securities transactions were reported in this filing.

What Was Disclosed

This Form 4 discloses an open-market purchase by InspireMD director Paul Stuka of 30,000 common shares at $0.58 on November 17, 2026, bringing his direct holdings to 697,871 shares, with 731,397 additional shares held indirectly through Osiris Investment Partners, L.P.